Stock Details
JNJ is Johnson & Johnson's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 159.62$. Average daily volumn in 3 months 8.19M. Market cap 474.70B



Stock symbol : JNJ. Exchange : NYSE. Currency : USD
Lastest price : 152.16$. Total volume : 3.34M. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Johnson & Johnson (JNJ)
Last Price
152.16$
Change
-1.14
Volume
3.34M

Previous Close153.30
Open152.39
Day Range152.01-153.45
Bid0.00 x 800
Ask0.00 x 1k
Volume3.34M
Average Volume8.19M
Market Cap474.7B
Beta0.53
52 Week Range150.11-186.69
Trailing P/E22.61
Foward P/E13.97
Dividend (Yield %)2.95%
Ex-Dividend Date2023-02-17



Financial Details


According to Johnson & Johnson's financial reports the company's revenue in 2023 were 94.94B an increase( +1.08%) over the years 2022 revenue that were of 93.78B. In 2023 the company's total earnings were 17.94B while total earnings in 2022 were 20.88B(-15%).


Loading ...



Organization

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC ... allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Market Cap:
474.70B
Revenue:
94.94B
Total Assets:
187.38B
Total Cash:
14.13B


News about "Johnson & Johnson"

Johnson & Johnson will seek US Supreme Court review of talc bankruptcy case

Source from : NJBIZ - 8 hours ago

After Johnson & Johnson failed to convince a federal appeals court to revive its bid to use Chapter 11 bankruptcy as a way to freeze nearly 40,000 talc lawsuits, the New Brunswick-based health ...See details»


Ready to Buy the Dip? Johnson & Johnson Stock Is a Smart Buy

Source from : The Motley Fool - 10 days ago

Johnson & Johnson has increased annual revenue for seven consecutive years. The company is pointing to revenue growth between 4.5% and 5.5% this year. Its stock currently offers an attractive ...See details»


Johnson & Johnson Stock Gains On Plan to Split Into Two Separate Companies

Source from : TheStreet.com - 1 year ago

Johnson & Johnson said Friday it will split its $15 billion consumer health unit from its pharmaceutical and medical devices division within the next two years. Johnson & Johnson will spin-off its ...See details»


Johnson & Johnson to Buy Abiomed for $16.6B

Source from : MD&M East - 21 days ago

Johnson & Johnson just revved up its M&A engine in a big way. The New Brunswick, NJ-based company plans to acquire Abiomed in a deal valued at about $16.6 billion ($380 a share), which includes cash ...See details»


A history of Johnson & Johnson

Source from : pharmaphorum - 1 month ago

These kits had the aim of making childbirth safer for mother and babies. Johnson's Baby Powder also went on sale during this year and was extremely successful. Robert Wood's granddaughter ...See details»


Unusual Put Option Trade in Johnson & Johnson Worth $1,690.5K

Source from : 24/7 Wall St - 29 days ago

On February 24, 2023 at 15:39:39 (ET) an unusually large $1,690.50K block of Put contracts in Johnson & Johnson (JNJ) was bought, with a strike price of $180.00 / share, expiring in 112 days (on ...See details»


Johnson & Johnson seeks FDA emergency authorization for COVID-19 vaccine

Source from : CNET - 1 month ago

One week after announcing its single-dose vaccine was 66% effective overall in preventing COVID-19 in a global clinical trial, Johnson & Johnson submitted an application requesting the US Food ...See details»


Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Source from : Yahoo Finance - 26 days ago

Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...See details»


Johnson & Johnson: Creating Shareholder Value

Source from : Yahoo - 14 days ago

Johnson & Johnson (NYSE:JNJ), one of the world's largest health care companies, has been making waves in the industry with its diverse pharmaceutical pipeline, a mix of opportunities and ...See details»


Buy the Dip in Johnson & Johnson and Its Near-3% Dividend Yield

Source from : TheStreet.com - 1 month ago

Johnson & Johnson stock has fallen in seven straight weeks, trades at less than 15 times earnings and pays a near-3% dividend yield. Plus, support is nearby. Does that make it a buy candidate?See details»


Johnson & Johnson Reports Q4 and Full-Year 2022 Results

Source from : Yahoo Finance - 2 month ago

As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value." OVERALL FINANCIAL RESULTS Q4 Full Year ...See details»


Intelligent Automation At Johnson & Johnson

Source from : Forbes - 28 days ago

Automation projects in organizations are often small-scale and bottom-up, so I was pleased to learn that at least one large company, Johnson & Johnson, is taking a broad enterprise-wide approach ...See details»


If You Like Johnson & Johnson, You'll Love These Higher-Yielding SWANs

Source from : Seeking Alpha - 18 days ago

So naturally, the media is happy to try to scare investors with headlines like this. Kiyosaki is one of the most entertaining doomsday prophets. He has spent over a decade predicting imminent 90% ...See details»


Johnson & Johnson stock outperforms competitors on strong trading day

Source from : MarketWatch - 15 days ago

Shares of Johnson & Johnson JNJ inched 0.96% higher to $153.06 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.15% to ...See details»